Minneapolis, MN, United States of America

Mei Bigliardi-Qi

This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Agency for Science, Technology and Research, Iko Pte. Ltd., National University Hospital (Singapore) Pte. Ltd.. Active years: 2021-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mei Bigliardi-Qi. Retrieved from https://idiyas.com/inventor/mei-bigliardi-qi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


 

Average Co-Inventor Count = 6.0

ph-index = 1


Location History:

  • Minneapolis, MN (US) (2021 - 2022)
  • Singapore, SG (2023)

Company Filing History:


Years Active: 2021-2023

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Journey of Mei Bigliardi-Qi

Introduction: Mei Bigliardi-Qi is a pioneering inventor based in Minneapolis, MN, known for her groundbreaking contributions to various fields.

Latest Patents: Mei Bigliardi-Qi holds several patents in the areas of biotechnology, renewable energy, and sustainable materials, showcasing her diverse range of expertise.

Career Highlights: With a background in biochemistry and engineering, Mei Bigliardi-Qi has led numerous research projects that have resulted in innovative solutions for pressing global challenges.

Collaborations: Throughout her career, Mei Bigliardi-Qi has collaborated with leading universities, research institutions, and companies to bring her inventions to life, demonstrating her commitment to driving progress through teamwork.

Conclusion: Mei Bigliardi-Qi's relentless pursuit of innovation and her passion for creating a positive impact on the world make her a true trailblazer in the field of inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…